Back to search results

Cervical and Endometrial Cancer Screening in Transgender and Gender Diverse Individuals

This study is looking at how often transgender and gender diverse (TGD) individuals get screened for cervical cancer and have endometrial sampling (a procedure to check the lining of the uterus) before a gender-affirming hysterectomy (surgery to remove the uterus). Researchers want to understand if these tests are needed and explore better ways to offer them. The study is observational, meaning there are no interventions or treatments given. It aims to enroll 40 participants who are 18 years or older, can speak English, and are TGD individuals who have had or plan to have a hysterectomy. The main goals are to measure screening rates and see if HPV self-testing (a way to check for human papillomavirus, which can cause cervical cancer) changes these rates over 36 months.

Study design
This is an observational study, meaning no interventions are given. It plans to include 40 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 36 months to measure screening rates.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07075731

Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy

Recruiting
Not specifiedAges 18+Observational
University of Minnesota
~40 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:No intervention

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rates of cervical cancer screening and endometrial sampling in TGD individuals
Measured over Month 36
+1 more outcome measured

Conditions

Cancer Screening
Transgender
Gender Diverse Populations

Explore related trials

Cervical CarcinomaEndometrial Carcinoma

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Samantha Hoffman, MD · PRINCIPAL_INVESTIGATOR · University of Minnesota

Who to contact

Samantha Hoffman, MD
[email protected]
(612)273-7117
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years and older
Able to provide voluntary written consent prior to the performance of any research related activity. Patients who can provide informed consent
Able to understand, speak, read, and write in English
Patients who have undergone hysterectomy, or plan to have a hysterectomy
Patients who are transgender and gender diverse"

Exclusion

Opted out of research
\<18 years old
Lacks capacity to consent/has diminished capacity to consent
Cannot provide informed consent
Those on the study's community advisory board

What this trial measures

  • Rates of cervical cancer screening and endometrial sampling in TGD individualsMonth 36

    Describe the rates of cervical cancer screening and endometrial sampling in TGD individuals undergoing hysterectomy in the MHealth Fairview System between January 2014-June 2024.

  • Whether HPV self-testing affects the rates of cervical cancer screening in TGD individualsMonth 36

    Describe the rates of cervical and endometrial cancer and their precursor lesions on pathology after hysterectomy that was undiagnosed prior to hysterectomy in TGD individuals in the MHealth Fairview System between January 2014-June 2024.